We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Merck (MRK) Beats Stock Market Upswing: What Investors Need to Know
Read MoreHide Full Article
In the latest trading session, Merck (MRK - Free Report) closed at $141.94, marking a +1.72% move from the previous day. The stock exceeded the S&P 500, which registered a gain of 0.58% for the day. Meanwhile, the Dow gained 0.49%, and the Nasdaq, a tech-heavy index, added 0.45%.
Prior to today's trading, shares of the pharmaceutical company had lost 7.18% lagged the Medical sector's loss of 4.26% and the S&P 500's gain of 0.84%.
Market participants will be closely following the financial results of Merck in its upcoming release. The company plans to announce its earnings on October 29, 2026. The company is forecasted to report an EPS of $2.25, showcasing a 12.79% downward movement from the corresponding quarter of the prior year. Meanwhile, the latest consensus estimate predicts the revenue to be $17.52 billion, indicating a 1.39% increase compared to the same quarter of the previous year.
MRK's full-year Zacks Consensus Estimates are calling for earnings of $2.77 per share and revenue of $67.25 billion. These results would represent year-over-year changes of -69.15% and +3.44%, respectively.
Investors should also pay attention to any latest changes in analyst estimates for Merck. Such recent modifications usually signify the changing landscape of near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. The Zacks Consensus EPS estimate has moved 0.07% lower within the past month. Merck currently has a Zacks Rank of #3 (Hold).
Looking at its valuation, Merck is holding a Forward P/E ratio of 50.47. This represents a premium compared to its industry average Forward P/E of 15.89.
Meanwhile, MRK's PEG ratio is currently 6.07. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Large Cap Pharmaceuticals industry currently had an average PEG ratio of 1.86 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 100, placing it within the top 41% of over 250 industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.
View the Zacks #1 Rank List
Image: Bigstock
Merck (MRK) Beats Stock Market Upswing: What Investors Need to Know
In the latest trading session, Merck (MRK - Free Report) closed at $141.94, marking a +1.72% move from the previous day. The stock exceeded the S&P 500, which registered a gain of 0.58% for the day. Meanwhile, the Dow gained 0.49%, and the Nasdaq, a tech-heavy index, added 0.45%.
Prior to today's trading, shares of the pharmaceutical company had lost 7.18% lagged the Medical sector's loss of 4.26% and the S&P 500's gain of 0.84%.
Market participants will be closely following the financial results of Merck in its upcoming release. The company plans to announce its earnings on October 29, 2026. The company is forecasted to report an EPS of $2.25, showcasing a 12.79% downward movement from the corresponding quarter of the prior year. Meanwhile, the latest consensus estimate predicts the revenue to be $17.52 billion, indicating a 1.39% increase compared to the same quarter of the previous year.
MRK's full-year Zacks Consensus Estimates are calling for earnings of $2.77 per share and revenue of $67.25 billion. These results would represent year-over-year changes of -69.15% and +3.44%, respectively.
Investors should also pay attention to any latest changes in analyst estimates for Merck. Such recent modifications usually signify the changing landscape of near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. The Zacks Consensus EPS estimate has moved 0.07% lower within the past month. Merck currently has a Zacks Rank of #3 (Hold).
Looking at its valuation, Merck is holding a Forward P/E ratio of 50.47. This represents a premium compared to its industry average Forward P/E of 15.89.
Meanwhile, MRK's PEG ratio is currently 6.07. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Large Cap Pharmaceuticals industry currently had an average PEG ratio of 1.86 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 100, placing it within the top 41% of over 250 industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.